Imugene Limited (ASX:IMU)

51.0¢

right-arrow Created with Sketch. -0.02 (-3.77%)
MCAP $2.910B
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

26/11/2021IMUImugene Limited
798
MCap
23/11/2021IMUImugene Limited
22/11/2021IMUImugene Limited
22/11/2021IMUImugene Limited
22/11/2021IMUImugene Limited
19/11/2021IMUImugene Limited
76,990
MCap
19/11/2021IMUImugene Limited
19/11/2021IMUImugene Limited
16,433
MCap

Company Overview

Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.

IMU in the news

Imugene (IMU) secures a new clinical trial supply agreement with Pfizer Inc…
Imugene (IMU) teams up with US-based Eureka Therapeutics to test a combination…
Imugene (IMU) announced that cancer and research centre, City of Hope, has…
Imugene (IMU) receives notice of grant from the Japanese Patent Office for…

Search Previous Announcements